ALX Oncology to present updated results from Phase 2 ASPEN-06 trial

ALX Oncology (ALXO) announced that the updated results from its Phase 2 ASPEN-06 clinical trial have been accepted for oral presentation at the 2025 American Society of Clinical Oncology, ASCO, Gastrointestinal Cancers Symposium, which will be held in San Francisco from January 23 – 25, 2025. ASPEN-06 is a randomized, multi-center, international trial evaluating evorpacept, ALX Oncology’s investigational CD47-blocking therapeutic that uniquely combines a high-affinity CD47-binding domain with an inactivated proprietary Fc domain, in combination with trastuzumab, CYRAMZA and paclitaxel against TRP alone for the treatment of patients with HER2-positive gastric/gastroesophageal junction cancer, where all patients had received an anti-HER2 agent in prior lines of therapy.